Holen Sie sich die Stockscreener-App
98.50
7.95%
7.25
Handel nachbörslich:
98.50
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RVTY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$91.25
Offen:
$93.52
24-Stunden-Volumen:
1.64M
Relative Volume:
1.40
Marktkapitalisierung:
$10.94B
Einnahmen:
$2.72B
Nettoeinkommen (Verlust:
$254.30M
KGV:
47.67
EPS:
2.0665
Netto-Cashflow:
$564.37M
1W Leistung:
+6.11%
1M Leistung:
+3.84%
6M Leistung:
-18.16%
1J Leistung:
-6.01%
1-Tages-Spanne:
$92.98
$98.78
1-Wochen-Bereich:
$89.39
$98.78
52-Wochen-Spanne:
$88.53
$129.50
Revvity Inc Stock (RVTY) Company Profile
Firmenname
Revvity Inc
Sektor
Branche
Telefon
781-663-6900
Adresse
77 4TH AVENUE, WALTHAM
Vergleichen Sie RVTY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RVTY
Revvity Inc
|
98.50 | 10.94B | 2.72B | 254.30M | 564.37M | 2.0665 |
|
TMO
Thermo Fisher Scientific Inc
|
432.59 | 159.40B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
200.83 | 141.27B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
509.53 | 38.21B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
115.55 | 30.90B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
156.13 | 26.35B | 15.50B | 1.33B | 2.16B | 7.34 |
Revvity Inc Stock (RVTY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-01 | Hochstufung | UBS | Neutral → Buy |
| 2025-01-10 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-12-13 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-15 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-07-08 | Eingeleitet | Leerink Partners | Outperform |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-01-16 | Herabstufung | UBS | Buy → Neutral |
| 2024-01-04 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-12-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-07-19 | Eingeleitet | Raymond James | Outperform |
| 2023-05-23 | Fortgesetzt | Goldman | Buy |
Alle ansehen
Revvity Inc Aktie (RVTY) Neueste Nachrichten
Repligen, Bruker, Agilent, Medpace, and Revvity Shares Skyrocket, What You Need To Know - FinancialContent
Revvity: Despite Facing Multiple Headwinds, Shares Are A Buy (NYSE:RVTY) - Seeking Alpha
High Content Screening Market Global Forecasts 2025-2030 - GlobeNewswire
High Content Screening Market Global Forecasts 2025-2030 with Danaher, Revvity, BD, Carl Zeiss, Merck, and Thermo Fisher Scientific Dominating the $2.19 Billion Market - Yahoo Finance
Revvity joins peers Thermo Fisher, Danaher in tariff warning, maintains profit outlook - MSN
Revvity Announces Financial Results for the First Quarter of 2025 - ADVFN
UBS Upgrades Revvity (BMV:RVTY) - Nasdaq
UBS Upgrades Revvity (BIT:1RVTY) - Nasdaq
UBS lifts Revvity stock rating to Buy, cuts price target to $115 - Investing.com Australia
UBS Upgrades Revvity (LSE:0KHE) - Nasdaq
UBS Upgrades Revvity (RVTY) - Nasdaq
UBS Boosts Revvity (RVTY) Rating to Buy Amid Growth Prospects | - GuruFocus
UBS lifts Revvity stock rating to Buy, cuts price target to $115 By Investing.com - Investing.com South Africa
UBS Upgrades Revvity to Buy from Neutral, Cuts Price Target to $115 From $145 - marketscreener.com
UBS Boosts Revvity (RVTY) Rating to Buy Amid Growth Prospects | RVTY Stock News - GuruFocus
Revvity to Present at Upcoming Investor Conferences | RVTY Stock News - GuruFocus
KeyBanc Adjusts Revvity's Price Target to $135 From $145 - marketscreener.com
Revvity CEO and CFO to Share Strategic Vision at BofA and Goldman Sachs Healthcare Conferences - Stock Titan
Revvity to Present at Upcoming Investor Conferences - Business Wire
Revvity Reports Strong Q1 2025 Financial Results - TipRanks
Revvity reaffirms 2025 guidance with $4.90-$5 EPS target amid robust software growth - MSN
Stifel maintains Revvity stock Hold rating, $120 target By Investing.com - Investing.com Canada
Revvity beats quarterly estimates on steady demand for medical equipment - MSN
Biotech Firm Revvity Reports Better-Than-Expected Earnings - MSN
Stifel maintains Revvity stock Hold rating, $120 target - Investing.com
Revvity (RVTY) Price Target Adjusted by Baird After Q1 Results | - GuruFocus
Revvity, Inc. (NYSE:RVTY) Q1 2025 Earnings Call Transcript - Insider Monkey
Revvity Exceeds Expectations: Strong Biotech Demand Fuels GrowthNews and Statistics - IndexBox
Revvity First Quarter 2025 Earnings: EPS Beats Expectations - Yahoo Finance
Raymond James Adjusts Price Target on Revvity to $120 From $145, Maintains Outperform Rating - marketscreener.com
Revvity Inc (RVTY) Q1 2025 Earnings Call Highlights: Surpassing Expectations with Strong ... - Yahoo Finance
Revvity Inc (RVTY) Q1 2025 Earnings Call Highlights: Surpassing Expectations with Strong ... By GuruFocus - Investing.com Canada
Revvity Inc (RVTY) Q1 2025 Earnings Call Highlights: Surpassing - GuruFocus
Jefferies Updates Revvity (RVTY) Price Target Amid Market Develo - GuruFocus
Revvity’s Earnings Call: Balanced Growth Amid Challenges - TipRanks
Revvity (RVTY) Price Target Reduced by Citi to $135, Buy Rating Maintained | RVTY Stock News - GuruFocus
Jefferies Cuts Price Target on Revvity to $106 From $130 - marketscreener.com
Earnings call transcript: Revvity beats Q1 2025 earnings expectations - Investing.com
Earnings call transcript: Revvity beats Q1 2025 earnings expectations By Investing.com - Investing.com India
Revvity: Q1 Earnings Snapshot - The Wilton Bulletin
Revvity (RVTY) Exceeds Q1 Expectations with Robust Diagnostics G - GuruFocus
RVTY Rises as Q1 Earnings & Sales Beat Estimates, '25 Sales View Up - Nasdaq
Revvity Q1 2025 slides: 4% organic growth driven by strong Diagnostics performance - Investing.com
Evercore ISI Adjusts Price Target on Revvity to $116 From $125 - marketscreener.com
Revvity's Steady Demand Lifts Q1 Results Above Expectations - Finimize
Earnings Summary: Revvity (RVTY) reports higher revenue and earnings for Q1 2025 - AlphaStreet
Revvity Q1 Earnings Surpass Street Estimates, Investors Cheer 2025 Revised Revenue Guidance - MSN
Revvity (RVTY) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Life Science Tools Maker Revvity Delivers Strong Q1 Earnings Despite Evolving Macroeconomic Backdrop - Benzinga
Revvity (RVTY) Surpasses Q1 Estimates and Updates 2025 Outlook - GuruFocus
Revvity, Inc. (RVTY) Implements Majority Voting Standard Followi - GuruFocus
Finanzdaten der Revvity Inc-Aktie (RVTY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.60%
2.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):